Phase II trial of erlotinib in elderly patients with previously treated non-small cell lung cancer: Results of the lung oncology group in kyushu (LOGiK-0802)

Kazuhiko Yamada, Koichi Azuma, Masafumi Takeshita, Junji Uchino, Chinatsu Nishida, Takayuki Suetsugu, Akira Kondo, Taishi Harada, Hirofumi Eida, Junji Kishimoto, Goki Eriguchi, Koichi Takayama, Yoichi Nakanishi, Kenji Sugio

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)

Abstract

Background: As the incidence of lung cancer in the elderly is increasing worldwide, there exists a need to develop a clinically effective, less toxic therapy for this patient population. Although erlotinib has shown proven effectiveness against non-small cell lung cancer (NSCLC), few studies have prospectively investigated its application to elderly patients. Patients and Methods: Patients aged 75 years with advanced or recurrent NSCLC including wild-type EGFR who had previously received one or two chemotherapy regimens were enrolled in this trial. Erlotinib was initially administered at a dose of 150 mg/day orally until disease progression or unacceptable toxicities occurred. The primary endpoint was the objective response rate. Results: Forty patients were enrolled between May 2009 and January 2014.

Original languageEnglish
Pages (from-to)2881-2887
Number of pages7
JournalAnticancer research
Volume36
Issue number6
Publication statusPublished - Jun 2016

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of erlotinib in elderly patients with previously treated non-small cell lung cancer: Results of the lung oncology group in kyushu (LOGiK-0802)'. Together they form a unique fingerprint.

Cite this